News
Moderna’s $37B market cap is too high, despite COVID-19 vacc...
JP Morgan has downgraded its valuation of Moderna, saying its $37 billion market cap is way too high even if its COVID-19 vaccine mRNA-1273 succeeds in clinical trials.
